A novel group of antidiabetic drugs that constitutes the sodium glucose transporter 2 (SGLT2) inhibitors have displayed encouraging results in patients with chronic heart failure (CHF) having diabetes mellitus Type-2 (T2DM). Here, SLC5A2 is linked to congestive heart failure.